[Form 4] Standard BioTools Inc. Insider Trading Activity
Standard BioTools (LAB) 鈥� Form 4 insider filing: CFO Hanjoon Alex Kim reported the acquisition of 1,500,000 Restricted Stock Units (transaction code 鈥淎鈥�) on 01-Aug-2025. The award was granted at no cost and converts 1-for-1 into common shares. Vesting occurs 40 % on 20-Jul-2026 and the remaining 60 % on 20-Jul-2027, conditional upon his continued employment. Post-grant, Mr. Kim鈥檚 beneficial ownership rises to 2,440,564 LAB shares, a figure that includes 12,861 shares previously purchased through the Employee Stock Purchase Plan. No shares were sold and no derivative positions were reported; ownership remains direct.
The filing indicates long-term retention incentives and closer alignment between the CFO and shareholders, while flagging potential share dilution when the RSUs settle.
Standard BioTools (LAB) 鈥� Comunicazione insider Modulo 4: Il CFO Hanjoon Alex Kim ha dichiarato l'acquisizione di 1.500.000 Unit脿 Azionarie Vincolate (codice transazione 鈥淎鈥�) il 01-agosto-2025. Il premio 猫 stato concesso a titolo gratuito e si converte 1 a 1 in azioni ordinarie. Il vesting avviene per il 40% il 20-luglio-2026 e per il restante 60% il 20-luglio-2027, subordinato alla sua continua occupazione. Dopo la concessione, la propriet脿 beneficiaria del sig. Kim sale a 2.440.564 azioni LAB, cifra che include 12.861 azioni acquistate in precedenza tramite il Piano di Acquisto Azionario per i Dipendenti. Non sono state vendute azioni n茅 sono state segnalate posizioni derivative; la propriet脿 rimane diretta.
La comunicazione indica incentivi di lungo termine per la retention e un allineamento pi霉 stretto tra il CFO e gli azionisti, pur segnalando una potenziale diluizione delle azioni al momento della conversione delle RSU.
Standard BioTools (LAB) 鈥� Presentaci贸n insider Formulario 4: El CFO Hanjoon Alex Kim report贸 la adquisici贸n de 1.500.000 Unidades de Acciones Restringidas (c贸digo de transacci贸n 鈥淎鈥�) el 01-agosto-2025. La adjudicaci贸n fue otorgada sin costo y se convierte 1 a 1 en acciones ordinarias. La adquisici贸n se completa en un 40% el 20-julio-2026 y el 60% restante el 20-julio-2027, condicionado a la continuidad de su empleo. Tras la concesi贸n, la propiedad beneficiaria del Sr. Kim asciende a 2.440.564 acciones LAB, cifra que incluye 12.861 acciones previamente adquiridas a trav茅s del Plan de Compra de Acciones para Empleados. No se vendieron acciones ni se reportaron posiciones derivadas; la propiedad permanece directa.
La presentaci贸n indica incentivos de retenci贸n a largo plazo y una mayor alineaci贸n entre el CFO y los accionistas, al mismo tiempo que advierte sobre una potencial diluci贸n de acciones cuando se liquiden las RSU.
鞀ろ儬雼る摐 氚旍澊鞓ろ埓歃�(LAB) 鈥� 雮措秬鞛� 鞁犼碃靹� 鞏戩嫕 4: CFO 頃滌 鞎岆爥鞀� 旯�鞚� 2025雲� 8鞗� 1鞚检棎 1,500,000 鞝滍暅 欤检嫕 雼渼(瓯半灅 旖旊摐 鈥淎鈥�)毳� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞚� 氤挫儊鞚� 氍挫儊鞙茧 攵�鞐悩鞐堨溂氅� 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅╇媹雼�. 氩犾姢韺呾潃 2026雲� 7鞗� 20鞚检棎 40%, 雮橂ǜ歆� 60%電� 2027雲� 7鞗� 20鞚检棎 攴胳潣 歆�靻嶌爜鞚� 瓿犾毄 臁瓣贝 頃橃棎 鞚措（鞏挫雼堧嫟. 攵�鞐� 頉� 旯� 鞌潣 鞁れ 靻岇湢 欤检嫕鞚� 2,440,564 LAB 欤检嫕鞙茧 歃濌皜頄堨溂氅�, 鞚� 靾橃箻鞐愲姅 歆侅洂 欤检嫕 甑Г 瓿勴殟鞚� 韱淀暣 鞚挫爠鞐� 甑Г頃� 12,861欤缄皜 韽暔霅橃柎 鞛堨姷雼堧嫟. 欤检嫕 毵る弰雮� 韺岇儩靸來拡 韽靺� 氤搓碃電� 鞐嗢棃鞙茧┌ 靻岇湢甓岇潃 歆侅爲 靻岇湢 靸來儨毳� 鞙犾頃╇媹雼�.
鞚� 鞁犼碃靹滊姅 鞛リ赴 鞙犾 鞚胳劶韹半笇鞕� CFO鞕� 欤检＜ 臧勳潣 旮措皜頃� 鞝曤牞鞚� 雮橅儉雮措┌, RSU臧� 鞝曥偘霅� 霑� 鞛犾灛鞝� 欤检嫕 頋劃 臧�電レ劚鞚� 瓴疥碃頃╇媹雼�.
Standard BioTools (LAB) 鈥� D茅claration d鈥檌niti茅 Formulaire 4 : Le CFO Hanjoon Alex Kim a d茅clar茅 l鈥檃cquisition de 1 500 000 unit茅s d鈥檃ctions restreintes (code transaction 芦 A 禄) le 01 ao没t 2025. Cette attribution a 茅t茅 accord茅e sans co没t et se convertit 脿 raison de 1 pour 1 en actions ordinaires. Le vesting s鈥檈ffectue 脿 40 % le 20 juillet 2026 et les 60 % restants le 20 juillet 2027, sous condition de maintien de son emploi. Apr猫s cette attribution, la propri茅t茅 b茅n茅ficiaire de M. Kim s鈥櫭﹍猫ve 脿 2 440 564 actions LAB, chiffre incluant 12 861 actions pr茅c茅demment achet茅es via le Plan d鈥橝chat d鈥橝ctions Employ茅s. Aucune action n鈥檃 茅t茅 vendue et aucune position d茅riv茅e n鈥檃 茅t茅 signal茅e ; la propri茅t茅 reste directe.
Cette d茅claration indique des incitations 脿 la r茅tention 脿 long terme et un alignement renforc茅 entre le CFO et les actionnaires, tout en signalant une potentielle dilution des actions lors de la conversion des RSU.
Standard BioTools (LAB) 鈥� Insider-Meldung Formular 4: CFO Hanjoon Alex Kim meldete den Erwerb von 1.500.000 Restricted Stock Units (Transaktionscode 鈥濧鈥�) am 01. August 2025. Die Zuteilung erfolgte kostenfrei und wandelt sich 1:1 in Stammaktien um. Die Vesting erfolgt zu 40 % am 20. Juli 2026 und die restlichen 60 % am 20. Juli 2027, vorbehaltlich seiner weiteren Anstellung. Nach der Zuteilung steigt Herr Kims wirtschaftliches Eigentum auf 2.440.564 LAB-Aktien, eine Zahl, die 12.861 zuvor 眉ber den Mitarbeiteraktienkaufplan erworbene Aktien einschlie脽t. Es wurden keine Aktien verkauft und keine Derivatpositionen gemeldet; das Eigentum bleibt direkt.
Die Meldung weist auf langfristige Bindungsanreize und eine engere Ausrichtung zwischen dem CFO und den Aktion盲ren hin, w盲hrend sie eine potenzielle Aktienverw盲sserung bei der Abwicklung der RSUs signalisiert.
- 1.5 million RSU grant strengthens executive retention and aligns the CFO鈥檚 compensation with long-term shareholder value
- Conversion of the RSUs in 2026-27 could dilute existing shareholders by adding up to 1.5 million new shares
Insights
TL;DR: Large RSU grant ties CFO to 2026-27 performance; limited immediate market impact.
The 1.5 million RSU award is substantial for a company of Standard BioTools鈥� size and extends the CFO鈥檚 incentive horizon to July 2027. Such front-loaded, time-based vesting is common for retention but does not require specific performance hurdles. Investors gain comfort from greater insider ownership, yet eventual conversion could add roughly 1 %鈥�2 % to shares outstanding depending on future dilution levels. No open-market buying or selling occurred, so the signal is chiefly motivational rather than a valuation statement.
TL;DR: Neutral鈥攎otivates CFO but dilution risk two years out.
The grant boosts Kim鈥檚 stake to 2.44 million shares, aligning him financially with price appreciation. Because the RSUs vest over two years and were issued at $0, cash flow and near-term EPS are unaffected. Market reaction is typically muted for routine compensation grants; however, I will monitor cumulative equity awards as they can pressure future per-share metrics. Overall, the filing neither strengthens nor harms the short-term investment thesis.
Standard BioTools (LAB) 鈥� Comunicazione insider Modulo 4: Il CFO Hanjoon Alex Kim ha dichiarato l'acquisizione di 1.500.000 Unit脿 Azionarie Vincolate (codice transazione 鈥淎鈥�) il 01-agosto-2025. Il premio 猫 stato concesso a titolo gratuito e si converte 1 a 1 in azioni ordinarie. Il vesting avviene per il 40% il 20-luglio-2026 e per il restante 60% il 20-luglio-2027, subordinato alla sua continua occupazione. Dopo la concessione, la propriet脿 beneficiaria del sig. Kim sale a 2.440.564 azioni LAB, cifra che include 12.861 azioni acquistate in precedenza tramite il Piano di Acquisto Azionario per i Dipendenti. Non sono state vendute azioni n茅 sono state segnalate posizioni derivative; la propriet脿 rimane diretta.
La comunicazione indica incentivi di lungo termine per la retention e un allineamento pi霉 stretto tra il CFO e gli azionisti, pur segnalando una potenziale diluizione delle azioni al momento della conversione delle RSU.
Standard BioTools (LAB) 鈥� Presentaci贸n insider Formulario 4: El CFO Hanjoon Alex Kim report贸 la adquisici贸n de 1.500.000 Unidades de Acciones Restringidas (c贸digo de transacci贸n 鈥淎鈥�) el 01-agosto-2025. La adjudicaci贸n fue otorgada sin costo y se convierte 1 a 1 en acciones ordinarias. La adquisici贸n se completa en un 40% el 20-julio-2026 y el 60% restante el 20-julio-2027, condicionado a la continuidad de su empleo. Tras la concesi贸n, la propiedad beneficiaria del Sr. Kim asciende a 2.440.564 acciones LAB, cifra que incluye 12.861 acciones previamente adquiridas a trav茅s del Plan de Compra de Acciones para Empleados. No se vendieron acciones ni se reportaron posiciones derivadas; la propiedad permanece directa.
La presentaci贸n indica incentivos de retenci贸n a largo plazo y una mayor alineaci贸n entre el CFO y los accionistas, al mismo tiempo que advierte sobre una potencial diluci贸n de acciones cuando se liquiden las RSU.
鞀ろ儬雼る摐 氚旍澊鞓ろ埓歃�(LAB) 鈥� 雮措秬鞛� 鞁犼碃靹� 鞏戩嫕 4: CFO 頃滌 鞎岆爥鞀� 旯�鞚� 2025雲� 8鞗� 1鞚检棎 1,500,000 鞝滍暅 欤检嫕 雼渼(瓯半灅 旖旊摐 鈥淎鈥�)毳� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞚� 氤挫儊鞚� 氍挫儊鞙茧 攵�鞐悩鞐堨溂氅� 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅╇媹雼�. 氩犾姢韺呾潃 2026雲� 7鞗� 20鞚检棎 40%, 雮橂ǜ歆� 60%電� 2027雲� 7鞗� 20鞚检棎 攴胳潣 歆�靻嶌爜鞚� 瓿犾毄 臁瓣贝 頃橃棎 鞚措（鞏挫雼堧嫟. 攵�鞐� 頉� 旯� 鞌潣 鞁れ 靻岇湢 欤检嫕鞚� 2,440,564 LAB 欤检嫕鞙茧 歃濌皜頄堨溂氅�, 鞚� 靾橃箻鞐愲姅 歆侅洂 欤检嫕 甑Г 瓿勴殟鞚� 韱淀暣 鞚挫爠鞐� 甑Г頃� 12,861欤缄皜 韽暔霅橃柎 鞛堨姷雼堧嫟. 欤检嫕 毵る弰雮� 韺岇儩靸來拡 韽靺� 氤搓碃電� 鞐嗢棃鞙茧┌ 靻岇湢甓岇潃 歆侅爲 靻岇湢 靸來儨毳� 鞙犾頃╇媹雼�.
鞚� 鞁犼碃靹滊姅 鞛リ赴 鞙犾 鞚胳劶韹半笇鞕� CFO鞕� 欤检＜ 臧勳潣 旮措皜頃� 鞝曤牞鞚� 雮橅儉雮措┌, RSU臧� 鞝曥偘霅� 霑� 鞛犾灛鞝� 欤检嫕 頋劃 臧�電レ劚鞚� 瓴疥碃頃╇媹雼�.
Standard BioTools (LAB) 鈥� D茅claration d鈥檌niti茅 Formulaire 4 : Le CFO Hanjoon Alex Kim a d茅clar茅 l鈥檃cquisition de 1 500 000 unit茅s d鈥檃ctions restreintes (code transaction 芦 A 禄) le 01 ao没t 2025. Cette attribution a 茅t茅 accord茅e sans co没t et se convertit 脿 raison de 1 pour 1 en actions ordinaires. Le vesting s鈥檈ffectue 脿 40 % le 20 juillet 2026 et les 60 % restants le 20 juillet 2027, sous condition de maintien de son emploi. Apr猫s cette attribution, la propri茅t茅 b茅n茅ficiaire de M. Kim s鈥櫭﹍猫ve 脿 2 440 564 actions LAB, chiffre incluant 12 861 actions pr茅c茅demment achet茅es via le Plan d鈥橝chat d鈥橝ctions Employ茅s. Aucune action n鈥檃 茅t茅 vendue et aucune position d茅riv茅e n鈥檃 茅t茅 signal茅e ; la propri茅t茅 reste directe.
Cette d茅claration indique des incitations 脿 la r茅tention 脿 long terme et un alignement renforc茅 entre le CFO et les actionnaires, tout en signalant une potentielle dilution des actions lors de la conversion des RSU.
Standard BioTools (LAB) 鈥� Insider-Meldung Formular 4: CFO Hanjoon Alex Kim meldete den Erwerb von 1.500.000 Restricted Stock Units (Transaktionscode 鈥濧鈥�) am 01. August 2025. Die Zuteilung erfolgte kostenfrei und wandelt sich 1:1 in Stammaktien um. Die Vesting erfolgt zu 40 % am 20. Juli 2026 und die restlichen 60 % am 20. Juli 2027, vorbehaltlich seiner weiteren Anstellung. Nach der Zuteilung steigt Herr Kims wirtschaftliches Eigentum auf 2.440.564 LAB-Aktien, eine Zahl, die 12.861 zuvor 眉ber den Mitarbeiteraktienkaufplan erworbene Aktien einschlie脽t. Es wurden keine Aktien verkauft und keine Derivatpositionen gemeldet; das Eigentum bleibt direkt.
Die Meldung weist auf langfristige Bindungsanreize und eine engere Ausrichtung zwischen dem CFO und den Aktion盲ren hin, w盲hrend sie eine potenzielle Aktienverw盲sserung bei der Abwicklung der RSUs signalisiert.
FAQ
How many LAB shares did CFO Hanjoon Alex Kim acquire?
What is the vesting schedule for the new LAB RSUs?
What is the CFO鈥檚 total beneficial ownership after the grant?
Were any LAB shares sold in this Form 4 filing?
Does the RSU grant involve any cash outlay by the executive?
